5-Amino-1MQ
5A1MQSubcutaneous NNMT-inhibitor reference for metabolic research.
Also known as: 5-Amino-1-methylquinolinium
Overview
5-Amino-1MQ (5-amino-1-methylquinolinium) is a non-peptide small molecule investigated as a selective inhibitor of nicotinamide N-methyltransferase (NNMT). Current interest centers on metabolic signaling, NAD+ availability, mitochondrial function, and adipocyte biology; human evidence remains limited.
Preclinical and practitioner literature explores 5-Amino-1MQ for NNMT inhibition, NAD+ metabolism, mitochondrial-energy signaling, and adipocyte function. The cited clinical guide uses a 150–500 mcg daily subcutaneous reference range, but these amounts are not established approved dosing standards and should be read as educational source material rather than medical advice.
By inhibiting NNMT, 5-Amino-1MQ is studied for reducing nicotinamide methylation and preserving metabolites involved in cellular NAD+ and methyl-donor pathways. Preclinical work examines downstream effects on mitochondrial energetics, fat oxidation, and adipocyte metabolism.
Molecular information
Reviva supplies a 50 mg lyophilized research vial. Concentration calculations must use the actual vial strength and diluent volume; the cited guide’s 10 mg / 2 mL example is not directly transferable to this format.
Research applications
- NNMT-inhibition and NAD+ pathway research
- Mitochondrial-energy and fat-oxidation studies
- Adipocyte and body-composition research
- Tolerability and subcutaneous-administration research
Research protocols
Protocols summarized from published research models. Provided for scientific reference only — not dosing guidance for human use.
Observed effects timeline
Aggregated observations reported across research literature. Timing and magnitude vary by model and are not a guarantee of outcome.
Weeks 1–2
The cited guide begins at the lower reference range to assess tolerability, including energy, nausea, and injection-site response.
Weeks 3–8
Its standard phase uses once-daily administration with monitoring of metabolic markers, body composition, and tolerability.
Weeks 9–12
Higher reference amounts are presented only as a monitored phase, followed by a 4–6 week break.
Research compatibility
Describes how compounds are studied alongside one another in the literature. Not a recommendation to co-administer.
NAD+
The cited guide discusses complementary NAD+-pathway research, while evidence for combined human use remains limited.
Stimulants
The cited guide advises avoiding stimulant combinations initially because activation-related effects may overlap.
Blood-pressure or diabetes medication
Potential metabolic and cardiovascular overlap warrants professional review and close monitoring.
MAO inhibitors
The cited guide flags this combination for clinician review rather than unsupervised use.
How to reconstitute
Reviva’s product is a 50 mg lyophilized vial. Reconstitute it with 3 mL of bacteriostatic water, swirl gently, and refrigerate; do not reuse the cited guide’s 10 mg / 2 mL concentration calculation.
- 1Allow the vial to reach room temperature (15–20 minutes).
- 2Swab the stopper with alcohol and let it air dry.
- 3Add 3 mL of bacteriostatic water slowly down the vial wall.
- 4Swirl gently until dissolved — do not shake.
- 5Refrigerate at 2–8 °C, protect from light, and use within 30 days.
Quality indicators
Uniform lyophilized material
The vial should contain a consistent white to off-white cake or powder without discoloration.
Clear reconstituted solution
After gentle reconstitution, the solution should be clear, colorless, and free from visible particles.
Minor dissolvable clumping
Small clumps caused by transport may be acceptable only when they dissolve completely with gentle swirling.
Cloudiness or persistent particles
Do not use material that remains cloudy, discolored, or particulate after gentle mixing.
Reported observations & safety
Safety signals reported in the research literature. Compiled for scientific awareness — not medical advice.
- Human evidence is limited; most mechanistic support comes from preclinical NNMT and metabolic research.
- The cited guide notes possible injection-site irritation, nausea, digestive discomfort, or an activating energy sensation, particularly at higher reference amounts.
- The cited guide advises against use during pregnancy or breastfeeding and flags cardiovascular disease, severe organ dysfunction, eating disorders, and age under 21 for clinician review.
- This entry summarizes external educational material and does not establish a safe or effective human dose.
References & further reading
NNMT inhibition and adipose metabolism (preclinical)
Preclinical research reporting that NNMT inhibition can alter cellular NAD+ and methyl-donor metabolism in adipose models.
View study5-Amino-1MQ Dosage: Clinical Protocol, Benefits & Administration
Practitioner-authored educational guide used here for subcutaneous reference ranges, cycling, administration, storage, cautions, and monitoring context.
View studyTopics
This entry is provided for educational and informational purposes only. It is not medical advice, a dosing protocol, or a claim of therapeutic benefit. Research compounds are supplied strictly for laboratory and research use — not for human or veterinary consumption.
Sparse published data; largely preliminary or anecdotal.
5-Amino-1MQ is stocked as a research-grade compound, ≥99% by HPLC, third-party verified.
View in catalogue